Novel brain cancer treatment in the spotlight Print E-mail
By Staff and Wire Reports   
Tuesday, 19 April 2011 19:27
Bill Doyle, Chairman of Novocure, discusses the company's new FDA-approved treatment that fights brain tumor cells using electrical energy fields generated by a battery powered helmet.

 

We told you on Monday that while Novocure is not publicly traded yet, the Portsmouth, N.H., and Haifa, Israel, based company has been testing its device in other types of cancer, including non-small cell lung cancer, it already counts WFD Ventures, Pfizer Inc. and Johnson & Johnson among it's investors. 

We have been hearing strong rumors on Wall Street that the company will be going public soon and its one of several that we think could get a very nice valuation right out of the gate. In fact, this could be one of the highest flying initial public offerings (IPO) the biotech sector has seen in some time- especially given the anticipated commercial adoption and excitement surrouding the non-invasive technology on Wall Street among biotech heavy bankers like Rodman & Renshaw. The interview on CNBC today shows that our pulse check on that excitement is definitely on-target and discusses the price tag and type of revenue expected by the company.

More and more oncologists are excited by the possibilities being presented by "non-toxic" cancer treatments that are proving able to extend survival in patients with these deadly cancers. This particular technology uses electric fields to disrupt the division of cancer cells that allows tumors to grow and spread. The electric fields have little effect on healthy cells because they divide at a much slower rate, if at all, compared with cancer cells. The company pipeline shows that the technology has applications in other types of cancers. For decades, doctors have treated cancer with three methods: drugs, radiation or surgery.

See the interview here or below:




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter